$430,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"- Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield forFY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 - H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 - H.R. 5252, Having Overdoes Protection Equipment Act - Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act"
You can find more data on corporate lobbying on Quiver Quantitative.
EBS Insider Trading Activity
EBS insiders have traded $EBS stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $EBS stock by insiders over the last 6 months:
- COLEEN GLESSNER (EVP, Quality & Ethics, and CPL) sold 30,608 shares for an estimated $306,080
- RONALD RICHARD has made 0 purchases and 2 sales selling 21,984 shares for an estimated $263,077.
- DONALD W DEGOLYER has made 0 purchases and 2 sales selling 25,645 shares for an estimated $255,453.
- SUJATA TYAGI DAYAL sold 8,552 shares for an estimated $85,520
- KATHRYN C ZOON sold 7,086 shares for an estimated $62,852
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EBS Hedge Fund Activity
We have seen 86 institutional investors add shares of EBS stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 705,004 shares (+40.5%) to their portfolio in Q3 2025, for an estimated $6,218,135
- MILLENNIUM MANAGEMENT LLC removed 677,608 shares (-89.7%) from their portfolio in Q3 2025, for an estimated $5,976,502
- AQR CAPITAL MANAGEMENT LLC added 586,246 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,170,689
- JAIN GLOBAL LLC added 508,707 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,486,795
- PALISADE CAPITAL MANAGEMENT, LP added 326,260 shares (+29.7%) to their portfolio in Q3 2025, for an estimated $2,877,613
- DIMENSIONAL FUND ADVISORS LP added 291,308 shares (+15.8%) to their portfolio in Q3 2025, for an estimated $2,569,336
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 276,566 shares (+25.0%) to their portfolio in Q3 2025, for an estimated $2,439,312
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EBS Analyst Ratings
Wall Street analysts have issued reports on $EBS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/16/2025
To track analyst ratings and price targets for EBS, check out Quiver Quantitative's $EBS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
